This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Reconsidering the Risks and Benefits

Arch Intern Med. 2003;163:657-659.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE FIRST 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, lovastatin, obtained Food and Drug Administration approval in the United States in 1987.¹ Now, after a little more than 15 years of clinical availability, the statins have emerged at the forefront of pharmacological treatment of hypercholesterolemia.^2-7 As one large-scale statin trial after another reported significant relative risk reductions—of 24% to 37%—for coronary disease, and adverse event rates that rarely differed from placebo, these agents quickly became the "gold standard" for drugs affecting lipid metabolism. The enthusiasm for statins was so great, even a few years ago, that the suggestion of adding statins to the drinking water as their next logical application was a common joke among those in the field.

However, in August 2001, the manufacturer of the drug cerivastatin voluntarily withdrew this statin from the United States and other markets because of a disproportionate number of reports of rhabdomyolysis-associated deaths, especially when . . . [Full Text of this Article]

STATINS AND HEPATOTOXICITY


STATINS AND MYOPATHY

CONCLUSIONS


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Screening for Statin-Related Toxicity: The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
C. Christopher Smith, Lana I. Bernstein, Roger B. Davis, David M. Rind, and Robert H. Shmerling
Arch Intern Med. 2003;163(6):688-692.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drug induced myopathies
Mastaglia
PN 2006;6:4-13.
FULL TEXT  

Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta et al.
Circulation 2004;109:III-50-III-57.
ABSTRACT | FULL TEXT  

Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Vijan and Hayward
ANN INTERN MED 2004;140:650-658.
ABSTRACT | FULL TEXT  

Monitoring drug treatment
Pirmohamed and Ferner
BMJ 2003;327:1179-1181.
FULL TEXT  

How Often to Screen for Statin-Related Toxicity
Journal Watch Cardiology 2003;2003:3-3.
FULL TEXT  

Transaminase and CK Screening in Patients Who Take Statins
JWatch General 2003;2003:4-4.
FULL TEXT